Clinical Trial Update: Fluvoxamine for Long COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

An update indicates a Phase 2/3 trial of fluvoxamine for long COVID has completed, though no results are detailed in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid

Drugs mentioned

• Fluvoxamine (fluvoxamine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Long COVID | Phase 2, Phase 3 | Status: COMPLETED